Skip to main content
. Author manuscript; available in PMC: 2024 Apr 9.
Published in final edited form as: Eur J Cancer. 2023 Mar 23;186:172–184. doi: 10.1016/j.ejca.2023.03.015

Fig. 6.

Fig. 6.

Time to Definitive Deterioration for Selected Scales of Interest in the All-Comer Population. CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire; EORTC QLQ-EN24, EORTC QLQ-Endometrial, 24 questions; HR, hazard ratio; L, lenvatinib; NE, not estimable; P, pembrolizumab; TPC, treatment of physician’s choice.